MetaCap

Progyny (PGNY) vs Viemed Healthcare (VMD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Progyny (PGNY) has outperformed Viemed Healthcare (VMD) over the past year, gaining 38.1% versus a gain of 27.9%. Over five years, VMD leads with a +62.9% price change compared with -30.1% for PGNY. Progyny is the larger company by market cap ($2.63 billion vs $322.8 million), about 8.1 times the size, while Viemed Healthcare is growing revenue faster (+20.5% vs +10.4%).

On valuation, Progyny trades at a lower forward P/E (14.9x vs 21.3x for Viemed Healthcare). Viemed Healthcare converts more of its revenue into profit, with a net margin of 5.5% versus 4.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PGNY+38.09%VMD+27.93%
+91%+24%-43%
Nov 21, 20251 yearNov 20, 2026
PGNY-39.83%VMD+56.33%
+136%+25%-87%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PGNY versus VMD key metrics
MetricPGNYVMD
Share price$35.71$8.52
Market cap$2.63B$322.85M
1-day change+0.73%-1.05%
YTD return+39.06%+14.67%
1-year return+38.09%+27.93%
5-year return-30.08%+62.91%
P/E ratio (TTM)32.7622.42
Forward P/E14.8721.30
EPS (TTM)$1.09$0.38
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.29B$270.28M
Revenue growth (YoY)+10.40%+20.52%
Net income (latest FY)$58.52M$14.93M
Gross margin23.63%57.52%
Operating margin6.62%8.49%
Net margin4.54%5.53%
52-week high$37.21$12.61
52-week low$16.10$6.60
Distance from 52-week high-4.03%-32.43%
Analyst consensusstrong_buybuy
Avg. price target upside+5.71%+40.85%
Average volume1.10M247.43K
Shares outstanding73.65M37.89M
Employees8351,490
SectorHealth CareHealth Care
IndustryMisc Health and Biotechnology ServicesMisc Health and Biotechnology Services

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Progyny is about 8.1 times larger than Viemed Healthcare by market value ($2.63B vs $322.85M).
  • PGNY has outperformed VMD by 10.2 percentage points over the past year.
  • Progyny trades at a higher earnings multiple (32.8x vs 22.4x trailing P/E).
  • Viemed Healthcare grew revenue faster in its latest fiscal year (+20.52% vs +10.40%).

About Progyny

PGNY stock →

Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists.

Health Care · Misc Health and Biotechnology Services · 835 employees

About Viemed Healthcare

VMD stock →

Viemed Healthcare, Inc., through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The company provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD.

Health Care · Misc Health and Biotechnology Services · 1,490 employees

PGNY vs VMD FAQ

Which is bigger, Progyny or Viemed Healthcare?

Progyny (PGNY) is larger, with a market capitalization of $2.63B compared with $322.85M for Viemed Healthcare (VMD).

Which stock has performed better over the past year, PGNY or VMD?

PGNY returned +38.09% over the past 12 months, compared with +27.93% for VMD (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, PGNY or VMD?

VMD has the lower trailing P/E at 22.4, versus 32.8 for PGNY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Progyny and Viemed Healthcare in the same industry?

Yes. Both are classified in the Misc Health and Biotechnology Services industry within the Health Care sector.

More comparisons